Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas.
Loading...
Embargo End Date
ICR Authors
Authors
Jones, RL
Le Cesne, A
Ibrahim, T
Garcia Del Muro, X
Menge, F
Le Cesne, A
Ibrahim, T
Garcia Del Muro, X
Menge, F
Document Type
Journal Article
Date
2018-12-02
Date Accepted
Abstract
Health-related quality of life (HRQoL) is a patient-reported outcome that addresses patients' perceptions of symptoms across physical, emotional, cognitive and social domains. As HRQoL is currently rarely measured outside clinical trials in oncology, it must be inferred from patients' everyday performance during treatment. To gain insight into the HRQoL of advanced STS patients receiving palliative treatment in clinical practice, three case studies of patients treated with trabectedin are examined. Areas covered: The patient in Case 1 has maintained complete remission for more than 8 years after receiving nine cycles of second-line trabectedin followed by secondary surgery for recurrent myxoid liposarcoma, and was able to resume normal activities during trabectedin treatment. Case 2 describes 10 years' follow-up of a patient with myxoid liposarcoma who remains well after many lines of chemotherapy including extended use of trabectedin in the second line. The third case illustrates the feasibility of extending survival time in an elderly patient with metastatic leiomyosarcoma who was able to maintain a busy and active lifestyle while receiving second-line trabectedin. Expert commentary: Owing to its relatively benign safety profile, trabectedin frequently permits prolonged therapy and is generally well tolerated, often allowing patients to carry on with normal daily activities.
Citation
Expert review of anticancer therapy, 2018, 18 (12), pp. 1241 - 1248
Source Title
Publisher
TAYLOR & FRANCIS LTD
ISSN
1473-7140
eISSN
1744-8328
Collections
Research Team
Sarcoma Clinical Trials (R Jones)